Novo Nordisk's $3.33 Billion Trading Volume Slides to Top 3 as Stock Dives 7.25% on New CEO and Profit Warning

On July 30, 2025, Novo Nordisk (NVO) traded with a volume of $3.33 billion, marking a 44.84% decline from the previous day’s trading activity. The stock closed down 7.25%, reflecting heightened investor anxiety amid strategic shifts at the company.

The sharp decline followed Novo’s announcement of a new CEO, Maziar Mike Doustdar, alongside a significant downward revision of its 2025 financial guidance. The firm cut its operating profit growth forecast to 10–16% and trimmed top-line growth expectations, citing weaker-than-anticipated U.S. sales for Wegovy and Ozempic. This pattern of “clearing the deck” for a leadership transition—pairing executive changes with profit warnings—has become a common practice, according to analysts, to reset investor expectations and provide the new CEO with a clearer path to performance improvement.

Technical indicators underscore the bearish momentum. The stock’s RSI stands at 26.27, signaling oversold conditions, while the 200-day moving average remains far above current prices. High-leverage put options, such as NVO20250808P50 and NVO20250808P49, highlight aggressive short-side positioning as traders anticipate further declines. These options exhibit elevated gamma and leverage, amplifying potential gains if the stock breaches key support levels.

The backtest of Novo’s historical performance after intraday plunges of at least 7% reveals a statistically favorable short-to-medium-term outlook. The 3-day win rate stands at 57.27%, with 62.87% of trades showing gains within 30 days. The maximum return during the test period reached 4.67% on day 58, illustrating the stock’s capacity to rebound despite initial volatility.